drugset / Trial / NCT07444606
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the recommended dose level and recommended number of injections of the study agent DNX-2401 that can be given to patients with metastatic melanoma that have intracranial and/or extracranial lesions.
Timeline
- Start
- 2026-08-31
- Primary completion
- 2027-01-30
- Completion
- 2029-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tasadenoturev | Unknown | — | Other |